Evidence map›Paper›PMID 42379141›Full record

ArticleNeuropsychopharmacology reports2026

Contribution of the Serotonin 5-HT

Daisuke Ibi, Rika Takaba, Keisuke Yoshida, Ririna Kawase, Hiroko Kitagawa, Momoko Matsushita, Kana Ito, Shoya Uno, Fumiya Nishimura, Shinji Kitagaki and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Daisuke IbiDepartment of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Rika TakabaDepartment of Chemical Pharmacology, Graduate School of Pharmacy, Meijo University, Nagoya, Japan.
Keisuke YoshidaDepartment of Medicinal Chemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Ririna KawaseDepartment of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Hiroko KitagawaDepartment of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Momoko MatsushitaDepartment of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Kana ItoDepartment of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Shoya UnoDepartment of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Fumiya NishimuraDepartment of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Shinji KitagakiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Masayuki HiramatsuDepartment of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan.

Funding

Brain Science FoundationHori Sciences and Arts FoundationJapan Society for the Promotion of Science 22K06872Japan Society for the Promotion of Science 26K09675NOVARTIS Foundation (Japan) for the Promotion of ScienceResearch Center for Psychedelic Therapy from the Research Institute of Meijo UniversityResearch Foundation for Pharmaceutical SciencesSENSHIN Medical Research FoundationSmoking Research FoundationTakahashi Industrial and Economic Research FoundationTakeda Science Foundation
6 · The paper itself

Abstract

Psychedelics such as psilocybin and lysergic acid diethylamide (LSD) exert hallucinogenic effects through stimulation of serotonin 5-HT

Indexed as

HallucinogensPsilocybinReceptor, Serotonin, 5-HT2ASocial BehaviorSocial DefeatStress, PsychologicalAnimalsBehavior, AnimalMaleMiceMice, Inbred C57BLSerotonin 5-HT2 Receptor AgonistsSerotonin 5-HT2 Receptor AntagonistsHallucinogenspsilocinPsilocybinReceptor, Serotonin, 5-HT2ASerotonin 5-HT2 Receptor AgonistsSerotonin 5-HT2 Receptor Antagonistspsilocinserotonin 5‐HT2A receptorsocial defeat stress

Identifiers

PMID42379141
PMCPMC13318401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.